Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis

World Psychiatry

Volumn 17, Issue 3, 2018, Pages 330-340

  Carbon, Maren ^a   Kane, John M ^a,b,c,d   Leucht, Stefan ^d   Correll, Christoph U ^a,b,c,e  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

annualized incidence; aripiprazole; clozapine; first generation antipsychotics; meta analysis; randomized controlled studies; schizophrenia; second generation antipsychotics; Tardive dyskinesia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUPHENAZINE; HALOPERIDOL; LURASIDONE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN ANTAGONIST; ZIPRASIDONE;

ARTICLE; COMPARATIVE STUDY; DOSAGE SCHEDULE COMPARISON; DRUG MEGADOSE; HUMAN; INCIDENCE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA;

EID: 85047827592     PISSN: 17238617     EISSN: 20515545     Source Type: Journal    
DOI: 10.1002/wps.20579     Document Type: Article

References (83)

1. Yassa R, Jones BD. Complications of tardive dyskinesia: a review. Psychosomatics 1985;26:305-7.
2. Strassnig M, Rosenfeld A, Harvey PD. Tardive dyskinesia: motor system impairments, cognition and everyday functioning. CNS Spectr 2017;7:1-8.
3. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161:414-25.
4. Peluso MJ, Lewis SW, Barnes TR et al. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br J Psychiatry 2012;200:387-92.
5. Miller DD, Caroff SN, Davis SM et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 2008;193:279-88.
6. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486-7.
7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. Arlington: American Psychiatric Publishing, 2013.
8. Komossa K, Rummel-Kluge C, Hunger H et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010;3:CD006654.
9. Komossa K, Rummel-Kluge C, Schmid F et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010;1:CD006625.
10. Haddad PM, Das A, Keyhani S et al. Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons. J Psychopharmacol 2012;26:15-26.
11. Carbon M, Hsieh CH, Kane JM et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry 2017;78:e264-78.
12. Jankelowitz SK. Treatment of neurolept-induced tardive dyskinesia. Neuropsychiatr Dis Treat 2013;9:1371-80.
13. Leucht S, Kissling W, Davis JM. How to read and understand and use systematic reviews and meta-analyses. Acta Psychiatr Scand 2009;119:443-50.
14. Leucht S, Samara M, Heres S et al. Dose equivalents for antipsychotic drugs: the DDD method. Schizophr Bull 2016;42(Suppl. 1):S90-4.
15. Beasley CM, Dellva MA, Tamura RN et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999;174:23-30.
16. Bouchard RH. Longitudinal comparative study of risperidone vs classical neuroleptics in the treatment of schizophrenia: 24 months of observation. Encéphale 2002;28:S31-2.
17. Carrière P, Bonhomme D, Lempérière T. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur Psychiatry 2000;15:321-9.
18. Colonna L, Saleem P, Dondey-Nouvel L et al. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol 2000;15:13-22.
19. Csernansky JG, Mahmoud R, Brenner R et al. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22.
20. de Jesus Mari J, Lima MS, Costa AN et al. The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders. Eur Arch Psychiatry Clin Neurosci 2004;254:356-61.
21. Dossenbach MR, Folnegovic-Smalc V, Hotujac L et al. Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:311-8.
22. Findling RL, Johnson JL, McClellan J et al. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry 2010;49:583-94.
23. Gaebel W, Riesbeck M, Wolwer W et al. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 2007;68:1763-74.
24. Gharabawi GM, Bossie CA, Zhu Y. New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidol. Am J Psychiatry 2006;163:938-9.
25. Girgis RR, Phillips MR, Li X et al. Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry 2011;199:281-8.
26. Glick ID, Marder SR. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2005;66:638-41.
27. Green AI, Lieberman JA, Hamer RM et al. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res 2006;86:234-43.
28. Grunder G, Heinze M, Cordes J et al. Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study. Lancet Psychiatry 2016;3:717-29.
29. Hirsch SR, Kissling W, Bauml J et al. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 2002;63:516-23.
30. Kahn RS, Fleischhacker WW, Boter H et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371:1085-97.
31. Keefe RS, Young CA, Rock SL et al. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res 2006;81:1-15.
32. Kinon BJ, Kollack-Walker S, Jeste D et al. Incidence of tardive dyskinesia in older adult patients treated with olanzapine or conventional antipsychotics. J Geriatr Psychiatry Neurol 2015;28:67-79.
33. Kongsakon R, Trinidad-Onate P, Chaudhry HR et al. Asian outpatients with schizophrenia: a double-blind randomized comparison of quality of life and clinical outcomes for patients treated with olanzapine or haloperidol. J Med Assoc Thai 2006;89:1157-70.
34. Lewis SW, Davies L, Jones PB et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess 2006;10:1-165.
35. Marder SR, Glynn SM, Wirshing WC et al. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry 2003;160:1405-12.
36. McEvoy JP, Byerly M, Hamer RM et al. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA 2014;311:1978-87.
37. Meltzer HY, Bobo WV, Lee MA et al. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia. Psychiatry Res 2010;177:286-93.
38. Miller DD, Eudicone JM, Pikalov A et al. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. J Clin Psychiatry 2007;68:1901-6.
39. Parabiaghi A, Tettamanti M, D'Avanzo B et al. Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol. Acta Psychiatr Scand 2016;133:63-75.
40. Potkin SG, Weiden PJ, Loebel AD et al. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol. Int J Neuropsychopharmacol 2009;12:1233-48.
41. Purdon SE, Jones BD, Stip E et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 2000;57:249-58.
42. Rosenheck R, Cramer J, Xu W et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med 1997;337:809-15.
43. Tohen M, Baker RW, Altshuler LL et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002;159:1011-7.
44. Tollefson GD, Beasley CM Jr, Tran PV et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
45. Tyrer P, Oliver-Africano PC, Ahmed Z et al. Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. Lancet 2008;371:57-63.
46. Tollefson GD, Beasley CM Jr, Tamura RN et al. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997;154:1248-54.
47. Buchanan RW, Panagides J, Zhao J et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol 2012;32:36-45.
48. Arango C, Robles O, Parellada M et al. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry 2009;18:418-28.
49. Breier A, Berg PH, Thakore JH et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 2005;162:1879-87.
50. Ciudad A, Alvarez E, Bousono M et al. Safety and tolerability of olanzapine versus risperidone: a one-year randomized study in outpatients with schizophrenia with prominent negative symptoms. Actas Esp Psiquiatr 2007;35:105-14.
51. Cuesta MJ, Garcia de Jalon E, Campos MS et al. Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis. Br J Psychiatry 2009;194:439-45.
52. Johnsen E, Jorgensen HA, Kroken RA et al. Neurocognitive effectiveness of quetiapine, olanzapine, risperidone, and ziprasidone: a pragmatic, randomized trial. Eur Psychiatry 2013;28:174-84.
53. Kane JM, Osuntokun O, Kryzhanovskaya LA et al. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry 2009;70:572-81.
54. Keks NA, Ingham M, Khan A et al. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. Br J Psychiatry 2007;191:131-9.
55. Kinon BJ, Lipkovich I, Edwards SB et al. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol 2006;26:157-62.
56. Kinon BJ, Noordsy DL, Liu-Seifert H et al. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J Clin Psychopharmacol 2006;26:453-61.
57. McIntyre RS, Cohen M, Zhao J et al. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord 2010;126:358-65.
58. Schoemaker J, Naber D, Vrijland P et al. Long-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry 2010;43:138-46.
59. Tran PV, Hamilton SH, Kuntz AJ et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-18.
60. Lewis SW, Barnes TR, Davies L et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006;32:715-23.
61. McEvoy JP, Lieberman JA, Stroup TS et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-10.
62. Tollefson GD, Birkett MA, Kiesler GM et al. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry 2001;49:52-63.
63. Addington DE, Labelle A, Kulkarni J et al. A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study. Can J Psychiatry 2009;54:46-54.
64. Chengappa KNR, Turkin SR, Schlicht PJ et al. A pilot, 15-month, randomised effectiveness trial of risperidone long-acting injection (RLAI) versus oral atypical antipsychotic agents (AAP) in persons with bipolar disorder. Acta Neuropsychiatrica 2010;22:68-80.
65. Citrome L, Cucchiaro J, Sarma K et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol 2012;27:165-76.
66. Gaebel W, Schreiner A, Bergmans P et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology 2010;35:2367-77.
67. Macfadden W, Ma YW, Thomas Haskins J et al. A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry 2010;7:23-31.
68. Naber D, Hansen K, Forray C et al. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res 2015;168:498-504.
69. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47:27-38.
70. Leucht S, Pitschel-Walz G, Engel RR et al. Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002;159:180-90.
71. Tenback DE, van Harten PN, Slooff CJ et al. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry 2005;66:1130-3.
72. Woods SW, Morgenstern H, Saksa JR et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 2010;71:463-74.
73. Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-62.
74. Emsley RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull 1999;25:721-9.
75. Kenney C, Hunter C, Davidson A et al. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol 2008;48:379-84.
76. Matson JL, Mayville EA, Bielecki J et al. Tardive dyskinesia associated with metoclopramide in persons with developmental disabilities. Res Dev Disabil 2002;23:224-33.
77. Chouza C, Scaramelli A, Caamano JL et al. Parkinsonism, tardive dyskinesia, akathisia, and depression induced by flunarizine. Lancet 1986;1:1303-4.
78. Vandewalle W, Boon E, Sienaert P. Movement disorders due to modern antidepressants and mood stabilizers. Tijdschr Psychiatr 2015;57:132-7.
79. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974;31:67-72.
80. Czobor P, Van Dorn RA, Citrome L et al. Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies. Eur Neuropsychopharmacol 2015;25:1158-66.
81. Garcia-Cabeza I, Gomez JC, Sacristan JA et al. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). BMC Psychiatry 2001;1:7.
82. Manu P, Dima L, Shulman M et al. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatr Scand 2015;132:97-108.
83. Zutshi D, Cloud LJ, Factor SA. Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a university-based movement disorder clinic. Tremor Other Hyperkinet Mov 2014;4:266.